Vaccines against multiple subtypes of dengue virus

Patent metadata

Field	Value
Publication number	US-9987347-B2
Application number	US-201414775069-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.

First claim

What is claimed:

1. A nucleic acid construct for expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of Dengue virus, comprising:
an encoding nucleotide sequence that expresses the polypeptide, wherein the polypeptide includes consensus prME proteins from at least two different Dengue virus subtypes, and
a promoter that regulates expression of the polypeptide in the mammal and is operably linked to the encoding nucleotide sequence,
wherein the encoding nucleotide sequence comprises at least two nucleic acid sequences selected from the group consisting of a nucleotide sequence encoding SEQ ID NO: 2, a nucleotide sequence encoding SEQ ID NO: 4, a nucleotide sequence encoding SEQ ID NO: 6, and a nucleotide sequence encoding SEQ ID NO: 8.

2. The nucleic acid construct of claim 1 , further comprising an IgE leader sequence operatively linked to the 5′-end of the coding sequence and operably linked to the promoter.

3. The nucleic acid construct of claim 1 , further comprising a polyadenylation sequence attached to the 3′-end of the coding sequence.

4. The nucleic acid construct of claim 1 , wherein the nucleic acid construct is codon optimized.

5. The nucleic acid construct of claim 1 , wherein the encoding nucleotide sequence encodes a polypeptide that includes at least two prME proteins selected from the group consisting of dengue virus-subtype 1, dengue virus-subtype 2, dengue virus-subtype 3, and dengue virus-subtype 4.

6. The nucleic acid construct of claim 1 , wherein the encoding nucleotide sequence comprises at least two nucleic acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7.

7. A DNA plasmid vaccine for generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising:
at least one DNA plasmid for expressing at least one consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein at least one consensus dengue antigen is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8 and a combination thereof, and
a pharmaceutically acceptable excipient;
the DNA plasmid comprising a promoter operably linked to a coding sequence that encodes the consensus dengue antigen.

8. The DNA plasmid vaccine of claim 7 , wherein the DNA plasmid further comprises an IgE leader sequence attached to the 5′-end of the coding sequence and operably linked to the promoter.

9. The DNA plasmid vaccine of claim 7 , wherein the DNA plasmid further comprises a polyadenylation sequence attached to the 3′-end of the coding sequence.

10. The DNA plasmid vaccine of claim 7 , wherein the DNA plasmid is codon optimized.

11. The DNA plasmid vaccine of claim 7 , wherein the pharmaceutically acceptable excipient is an adjuvant.

12. The DNA plasmid vaccine of claim 11 , wherein the adjuvant is selected from the group consisting of: IL-12 and IL-15.

13. The DNA plasmid vaccine of claim 7 , wherein the pharmaceutically acceptable excipient is a transfection facilitating agent.

14. The DNA plasmid vaccine of claim 13 , wherein the transfection facilitating agent is a polyanion, polycation, or lipid.

15. The DNA plasmid vaccine of claim 13 , wherein the transfection facilitating agent is poly-L-glutamate at a concentration less than 6 mg/ml.

16. The DNA plasmid vaccine of claim 7 , wherein the DNA plasmid vaccine has a concentration of total DNA plasmid of 1 mg/ml or greater.

17. The DNA plasmid vaccine of claim 7 , wherein the vaccine comprises a plurality of unique DNA plasmids, wherein each of the plurality of unique DNA plasmids encodes a polypeptide comprising at least one consensus prME protein selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8.

18. The DNA plasmid vaccine of claim 7 , wherein the encoding nucleotide sequence comprises one or more sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7.

19. The DNA plasmid vaccine of claim 7 , comprising at least two different DNA plasmids that express a Dengue virus prME protein, the plasmids selected from the group consisting of:
a DNA plasmid comprising a sequence that encodes SEQ ID NO:2,
a DNA plasmid comprising a sequence that encodes SEQ ID NO:4,
a DNA plasmid comprising a sequence that encodes SEQ ID NO:6, and
a DNA plasmid comprising a sequence that encodes SEQ ID NO:8.

20. The DNA plasmid vaccine of claim 7 , comprising:
the DNA plasmid comprising a sequence that encodes SEQ ID NO:2,
the DNA plasmid comprising a sequence that encodes SEQ ID NO:4,
the DNA plasmid comprising a sequence that encodes SEQ ID NO:6, and
the DNA plasmid comprising a sequence that encodes SEQ ID NO:8.

21. The DNA plasmid vaccine of claim 7 , wherein the nucleotide sequence encoding SEQ ID NO:2 is SEQ ID NO: 1, wherein the nucleotide sequence encoding SEQ ID NO:4 is SEQ ID NO: 3, wherein the nucleotide sequence encoding SEQ ID NO:6 is SEQ ID NO: 5, and wherein the nucleotide sequence encoding SEQ ID NO:8 is SEQ ID NO: 7.

22. The DNA plasmid vaccine of claim 7 , wherein the mammal is a nonhuman primate.

23. The DNA plasmid vaccine of claim 7 , wherein the immune response is selected from the group consisting of a humoral response, a cellular response, and a combination thereof.

24. A method of eliciting an immune response against a plurality of subtypes of a dengue virus in a mammal, comprising,
delivering the DNA plasmid vaccine of claim 7 to tissue of the mammal, and
electroporating cells of the tissue with a pulse of energy at a constant current effective to permit entry of DNA plasmids in said DNA plasmid vaccine into the cells.

25. The method of claim 24 , wherein the delivering step comprises:
injecting the DNA plasmid vaccine into intradermic, subcutaneous or muscle tissue.

26. The method of claim 24 , further comprising:
presetting a current that is desired to be delivered to the tissue; and
electroporating cells of the tissue with a pulse of energy at a constant current that equals the preset current.

27. The method of claim 24 , wherein the electroporating step further comprises:
measuring the impedance in the electroporated cells;
adjusting energy level of the pulse of energy relative to the measured impedance to maintain a constant current in the electroporated cells;
wherein the measuring and adjusting steps occur within a lifetime of the pulse of energy.

28. The method of claim 24 , wherein the electroporating step comprises:
delivering the pulse of energy to a plurality of electrodes according to a pulse sequence pattern that delivers the pulse of energy in a decentralized pattern.

Assignees

• Inovio Pharmaceuticals Inc
• Weiner David B
• Yan Jian
• Sardesai Niranjan
• Univ Pennsylvania

Inventors

• Weiner David B
• Yan Jian
• Sardesai Niranjan

Classifications

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61K2039/55527

  Interleukins · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/575

  humoral response · CPC title